Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk

Inclusion Criteria:

• 1. Age ≥ 18 years 2. Moderate-severe or severe mitral regurgitation (≥ 3+) 3.Patient has New York Heart Association (NYHA) Functional Class II, III or ambulatoryIV 4. Patient is under guideline directed medical therapy, as reviewed and confirmedby the local multidisciplinary Heart Team, for at least one month 5. Patient ishigh-risk for open-heart surgery based on the assessment of the multidisciplinaryHeart Team using standard scoring systems and consideration of co-morbidities,frailty, and disability 6. Patient meets the anatomical criteria for HighLife valve

7. Patient is willing to participate in the study and provides signed informedconsent

Exclusion Criteria:

1. Any stroke/TIA within 30 days

2. Severe symptomatic carotid stenosis (> 70% by non-invasive imaging)

3. Active infections requiring antibiotic therapy

4. Active ulcer or gastro-intestinal bleeding in the past 3 months

5. History of bleeding diathesis, coagulopathy or refusal of future blood transfusion

6. Patients in whom TEE is not feasible

7. Patients who are pregnant or lactating, or plan to get pregnant in the next 12months.

8. Patient is unable to comply with the follow-up schedule and assessments

9. Participation in another clinical investigation at the time of inclusion

10. Patient has known allergies to the device components or contrast medium

11. Patient cannot tolerate anticoagulation or antiplatelet therapy

12. Patients with a life expectancy of less than 12 months due to non-cardiac conditions

13. Patient had permanent pacemaker, or similar device with implantable cardiac leads (i.e. resynchronization therapy) within the last 3 months